U.S. Markets open in 8 hrs 33 mins

The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

Zacks Equity Research

For Immediate Release

Chicago, IL – July 14, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boeing (NYSE: BA – Free Report ), AbbVie (NYSE: ABBV – Free Report ) and U.S. Bancorp (NYSE: USB – Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Friday’s Analyst Blog:

Top Stock Reports for Today: Boeing, AbbVie & U.S. Bank

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Boeing (NYSE: BA – Free Report ), AbbVie (NYSE: ABBV – Free Report ) and U.S. Bancorp (NYSE: USB – Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>

Boeing ’s shares have surged +56.9% over the past one-year, outperforming the Zacks Aerospace & Defense sector, which gained +24.6% during the same time period. The Zacks analyst stresses that rising demand for its commercial airplanes on the back of steady improvement in passenger and freight traffic is the major factor behind the surge in Boeing shares.

Recently, the company released 20-year market outlook, as per which it forecasts jetliner demand will increase by 3.6% over this period. Further, the company’s defense business stands out among its peers by virtue of its broadly diversified programs, strong order bookings and order backlog.

However, challenges including uncertain fate of high-cost programs, risks related to key project executions, order cancellations as well as stiff competition might have a negative impact on the company. (You can read the full research report on Boeing here >>> ).

Shares of AbbVie have gained +14.8% year to date, outperforming the large cap pharma industry, which has gained +11.3% over the same period. The Zacks analyst likes its key drug Humira’s performance. Sales should continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets.

Moreover, products like Viekira and Imbruvica have diversified AbbVie’s revenue base. AbbVie has a deep and promising pipeline and is also working on expanding its portfolio though additional deals. On the flip side, the Zacks analyst points out that Viekira faces intense pricing pressure and competition in the HCV market.

Additionally, quite a few companies are working on bringing Humira biosimilars to the market. Estimates remain stable ahead of the company’s Q2 earnings release. AbbVie has had a mixed record of earnings surprises in recent quarters. (You can read the full research report on AbbVie here >>> ).

U.S. Bancorp ’s shares have underperformed the Zacks categorized Regional Banks-Major industry over the last one year, gaining +25.8% vs.39.3%. Rising expenses and litigations remain key concerns. However, the Zacks analyst thinks the company’s growth prospects should get support from its solid business model, core franchise and diverse revenue streams.

Though the company raised its prime lending rate to 4.25%, following the recent Fed interest rate hike, easing of margin pressure is skeptical. Nevertheless, the approval of Financial Choice Act is expected to support U.S. Bancorp’s profitability going forward. Notably, the bank received the Fed's approval for its 2017 capital plan. (You can read the full research report on U.S. Bancorp here >>> ).

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on BA - FREE

Get the full Report on ABBV - FREE

Get the full Report on USB - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339



Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boeing Company (The) (BA) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
U.S. Bancorp (USB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research